IMMUNOBIOGRAM® (IMBG) PHARMACOECONOMIC  STUDY IN KIDNEY TRANSPLANTATION

Graft failure in Kidney Transplant is associated with high direct costs and a decrease in patients´ quality of life due to the high possibility of ending up in dialysis or retransplantation. New interventions are needed to improve immunosuppressive drugs adjustment in an individualized way to prevent graft failure, reduce related adverse events, and decrease the associated costs.

The IMMUNOBIOGRAM® was evaluated in a pharmacoeconomic study:

ECONOMIC EVALUATION OF IMMUNOBIOGRAM IN THE SELECTION AND DOSE TITRATION OF IMMUNOSUPPRESSIVE THERAPY IN KIDNEY TRANSPLANT PATIENTS IN SPAIN”

The objective of this evaluation was to estimate the economic impact of using the Immunobiogram® for the Spanish National-Health-System (NHS), given that it can help physicians to select the most appropriate IS and doses.

A hypothetical cohort (1,000 patients 1 year after renal transplantation) was modeled using a probabilistic second-order Monte Carlo simulation for a time horizon of 5 years under the Spanish NHS perspective. Only direct costs were considered.

The results of this evaluation showed that in patients with high risk of graft rejection, the use of the IMBG would entail a potential risk reduction, with a saving of costs per patient in 5 years of € 20,279, and a 100% saving probability.

 Patients with HIGH RISK of graft rejection

0
Savings of costs per patient
0
Years
0%
Saving probability

For stable, low risk patients, the use of the IMBG would entail an expected reduction in the adverse events rate with savings of € 3,328 per patient in 5 years, and a 99.5% saving probability.

 Patients with LOW RISK of graft rejection

0
Savings of costs per patient
0
Years
0%
Saving probability

Therefore, the routinely use of the Immunobiogram in patients one year after their kidney transplant may have considerable savings for the Spanish NHS.

Go to clinical Results
download IMBG RT ppt